Mandate

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

January 29, 2026 Banking and Finance

Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.

The AT1 bonds are perpetual with a first call option after five years, and they are intended to be admitted to trading on Nasdaq Stockholm. SEB acted as sole manager in connection with the bond issuance.
 
Borgo is a Swedish mortgage institution (Credit Market Company) which is under the supervision of the Swedish FSA. Borgo offers mortgages to the prime segment in Sweden as well as savings accounts. Mortgages are distributed by ICA Banken, Ikano, Söderberg & Partners, Sparbanken Syd, Lån & Spar Bank and Ålandsbanken. As a modern, highly digitalised player, Borgo aims to offer better mortgage terms to more people in an efficient, transparent and sustainable way. 
 
Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda, Caroline Krassén, August Ahlin and Nilufer Nouri.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026